References
- Brown RH, Al-Chalabi A, Longo DL. Amyotrophic Lateral Sclerosis. Longo DL, editor. N Engl J Med. 2017;377(2):162–172.
- Worms PM. The epidemiology of motor neuron diseases: a review of recent studies. J Neurol Sci. 2001;191(1–2):3–9.
- Prognosis and epidemiology of amyotrophic lateral sclerosis: analysis of a clinic population, 1997-2011 - PubMed [Internet]. [ cited 2022 Nov 12]. Available from: https://pubmed.ncbi.nlm.nih.gov/24195020/.
- Chiò A, Logroscino G, Traynor BJ, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology. 2013;41(2):118–130.
- Paganoni S, Macklin EA, Hendrix S, et al. Trial of sodium phenylbutyrate–taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383(10):919–930.
- FDA Approved Drug Products: sodium phenylbutyrate. Tablets or Powder, for oral administration.
- Sun Y, Bedlack R, Armon C, et al. ALSUntangled #64: butyrates. Amyotroph Lateral Scler Front Degener. 2022;23(7–8):638–643.
- Candido EPM, Reeves R, Davie JR. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell. 1978;14(1):105–113.
- Ryu H, Smith K, Camelo SI, et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem. 2005;93(5):1087–1098.
- Zhang Y, Wu S, Yi J, et al. Target intestinal microbiota to alleviate disease progression in amyotrophic lateral sclerosis. Clin Ther. 2017;39(2):322–336.
- Cudkowicz ME, Andres PL, Macdonald SA, et al. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph Lateral Scler. 2009;10(2):99–106.
- Rodrigues CMP, Solá S, Sharpe JC, et al. Tauroursodeoxycholic acid prevents bax-induced membrane perturbation and cytochrome c release in isolated mitochondria. Biochemistry. 2003;42(10):3070–3080.
- Vaz AR, Cunha C, Gomes C, et al. Glycoursodeoxycholic acid reduces matrix metalloproteinase-9 and caspase-9 activation in a cellular model of superoxide dismutase-1 neurodegeneration. Mol Neurobiol. 2015;51(3):864–877.
- Fels JA, Dash J, Leslie K, et al. Effects of PB-TURSO on the transcriptional and metabolic landscape of sporadic ALS fibroblasts. Ann Clin Transl Neurol. 2022;9(10):1551–1564.
- FDA Approved Drug Products: RELYVRIO (sodium phenylbutyrate and taurursodiol) for oral suspension.
- Parry GJ, Rodrigues CMP, Aranha MM, et al. Safety, tolerability, and cerebrospinal fluid penetration of ursodeoxycholic acid in patients with amyotrophic lateral sclerosis. Clin Neuropharmacol. 2010;33(1):17–21.
- Min J-H, Hong Y-H, Sung -J-J, et al. Oral solubilized ursodeoxycholic acid therapy in amyotrophic lateral sclerosis: a randomized cross-over trial. J Korean Med Sci. 2012;27(2):200.
- Elia AE, Lalli S, Monsurrò MR, et al. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur J Neurol. 2016;23(1):45–52.
- Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS - Full Text View - ClinicalTrials.gov [Internet]. [cited 2022 Nov 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT03800524?term=NCT03800524&draw=2&rank=1.
- Paganoni S, Hendrix S, Dickson SP, et al. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve. 2021;63(1):31–39.
- Paganoni S, Watkins C, Cawson M, et al. Survival analyses from the CENTAUR trial in amyotrophic lateral sclerosis: evaluating the impact of treatment crossover on outcomes. Muscle Nerve. 2022;66(2):136–141.
- Paganoni S, Hendrix S, Dickson SP, et al. Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial. J Neurol Neurosurg Psychiatry. 2022;93(8):871–875.
- Larghi A, Crosignani A, Battezzati PM, et al. Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: a pilot crossover study. Aliment Pharmacol Ther. 1997;11(2):409–414.
- Crosignani A, Battezzati PM, Setchell KD, et al. Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response study. Dig Dis Sci Internet]. 1996 [cited 2022 Dec 3];41. Available from: https://pubmed.ncbi.nlm.nih.gov/8674405/
- Health Canada Approved Drug Products: ALBRIOZA (sodium phenylbutyrate and ursodoxicoltaurine) Oral Powder for suspension.
- Sodium phenylbutyrate Prices, Coupons, Copay & Patient Assistance [Internet]. Drugs.com. [ cited 2022 Nov 12]. Available from: https://www.drugs.com/price-guide/sodium-phenylbutyrate.
- ICER Publishes Evidence Report on Treatments for Amyotrophic Lateral Sclerosis [Internet]. ICER. [ cited 2022 Nov 12]. Available from: https://icer.org/news-insights/press-releases/icer-publishes-evidence-report-on-treatments-for-amyotrophic-lateral-sclerosis/.